“Johnson & Johnson forecasts as much as 6% sales growth in 2024”
December 11, 2023
“Johnson & Johnson on Tuesday forecast revenue growth of 5% to 6% for the next year, as it banks on strong demand for cancer treatments Darzalex and Carvykti and resilient sales of blockbuster drug Stelara…
The company expects full-year adjusted operational profit of $10.55 to $10.75 per share in 2024, including a 15-cent impact from its recent acquisition of private medical device maker Laminar.
J&J’s 2024 revenue growth forecast excludes sales of its Covid vaccine…”
See the bold? Lawsuits are coming. It’s probably not a good idea to have a wait and see attitude for this stock.